Exviera dasabuvir: Preliminary Phase IIIb data

Preliminary data from 10 evaluable treatment-naive, non-cirrhotic patients with chronic HCV genotype 1 infection and severe renal impairment or end-stage renal disease (ESRD) in the first cohort of the open-label, U.S. Phase IIIb RUBY-I trial showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir with and without ribavirin for 12 weeks led to an SVR 4 weeks after the end of treatment in 100% of patients. No virologic failures have been reported to date. The first cohort is enrolling 20 patients without cirrhosis and the second cohort will enroll about 20 patients with and without compensated cirrhosis. The trial is evaluating 12 and 24 weeks of treatment with Viekirax and Exviera with and without ribavirin. Data were presented at the European Association for the Study of the Liver meeting in Vienna. ...